The U.S. Biosimilar Market: Do Analysts Have It Wrong?
White Paper|
By Barrett Rankin, Partner; Gautam Aggarwal, Partner; Alex Sherman, Strategy Consultant; Rachel Clare, Strategy Consultant
In this paper, Triangle Insights proposes a framework to more accurately predict biosimilar penetration by accounting for key factors influencing physicians, patients, and payers.
The U.S. Biosimilar Market: Do Analysts Have It Wrong?
Please submit the form below to view this resource.